Eight-Week Treatment Regimen Of Glecaprevir Plus Pibrentasvir May Lead To Similar Outcomes As 12-Week Regimen In Patients With HCV Genotypes 1 To 6, Study Indicates

Infectious Disease Advisor (1/3) reported researchers found in a phase 3b clinical trial that “eight weeks of treatment with glecaprevir/pibrentasvir was well tolerated in patients who were treatment-naïve with chronic hepatitis C virus (HCV) genotypes 1...